Determining the risk of neonatal jaundice within the first few days of life is an important investigation, as the time of discharge is often determined by the course of bilirubin. At present, no standardised method is used to predict the course of bilirubin. NeoPrediX B.1 can accurately predict individualised bilirubin progression for up to 60 hours using a science-based algorithm validated in a multicentre clinical trial. Implementing a novel, data-driven approach to routine use can help optimise clinical workflows and patient length of stay, as well as improve the quality of neonatal care.
- Individualised and optimised quality of care for every pregnant woman and for every newborn
- The first product on the NeoPrediX platform allows the prediction of the bilirubin course of up to 60 hours to optimise the patient's length of stay in the hospital and plan further treatment. The prediction is based on only a few standard clinical values
- Informed discharge decisions through early detection of neonatal jaundice
- Standardisation of neonatal care using an algorithm validated by a multicentre clinical trial
- Efficient decision-making supports clinical processes and reduces stressful situations for clinical staff
- Integration into common hospital information systems for the smooth running of decision-making processes in the clinic, without annoying data entry
Website
